Turning Point Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 27th, 2020 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • New York
Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,597,702 shares of the Company’s common stock, par value $0.0001 per share (“Stock”, and such shares, the “Firm Shares”) and, at the election of the Underwriters, up to 689,655 additional shares (the “Optional Shares”) of Stock. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares”.
